Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Durvalumab and Olaparib in HRD+ ED-SCLC
NCT06419179Phase 2Enrolling by invitation
- Sponsor
- University of Cologne
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in small cell lung cancer (SCLC), sponsored by University of Cologne. Primary endpoint: Progression-free survival at 2 years. Started Oct 2024; status: enrolling by invitation.
02
Drugs
olaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06419179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419179.